Filter posts

PTAB, IPRs and Uncertainty in the Patent System

The topic of inter partes reviews (IPRs) has dominated conversation in patent circles for the …

BIO's Statement Regarding SCOTUS Patent Review Decision

BIO issued the following statement following yesterday’s Supreme Court decision in the case of Cuozzo …

Will the PTAB Be A Roadblock for Biotech? Stories from Sessions at BIO 2016

We’re at the beginning of day 3 here at BIO 2016, and that means we’ve already had …

IP Sessions at BIO 2016--Come Join us in San Francisco!

That’s right, we’re back at it again! This year’s BIO International Convention will host several innovative …

What We’ll Be Talking about at the BIO Spring IPCC Conference

It’s time once again for BIO’s Spring IPCC Conference! BIO’s biannual Intellectual Property Counsels Committee …

"II Ca-Be-lly, or Not II Ca-Be-lly?”: Is The Famous Cabilly II Antibody Patent Near Extinction?

Guest post by Konstantin Linnik, Ph.D., Isaac Hubner, Ph.D, and Lana Gladstein, who are attorneys …

PTAB Ruling Proves Medical Innovation Under Attack

There’s more evidence today that the IPR system needs to be fixed. PTAB ruled on …

BIO on CNBC: IPR System Weakens Medical Innovation

Last night Ron Cohen, M.D., CEO of Acorda Therapeutics and BIO’s board chair, appeared on …

Here are the Facts about the IPR Kill Rate

FiercePhrma recently ran an article repeating a dubious analysis of the crisis caused by the …

IP Sessions at BIO 2015: The Evolving Landscape of Patentable Subject Matter

The IP Track at BIO 2015 had a number of incredible educational sessions concerning the …